Curcumin inhibits the progression of hyperlipidemia via OGT mediated O-GlcNAcylation modulation of APOC3
International Immunopharmacology · 2025
DOI: 10.1016/j.intimp.2024.113647 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Guotong Sun und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Hulunbuir Zhong Meng Hospital, Hulunbuir 021000, China; Department of Cardiology, Shouguang Hospital of T.C.M, Weifang 2627…. Hauptthemen laut MEDLINE: Curcumin, Hyperlipidemias, N-Acetylglucosaminyltransferases, Mice, Inbred C57BL. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Hubei Association for Science and Technology.
Abstract (Originalsprache)
The etiology of hyperlipidemia is complex, and our understanding of its underlying mechanisms is limited. Effective therapeutic strategies for hyperlipidemia remain elusive. This study aimed to confirm the effect of curcumin on hyperlipidemia treatment and elucidate the precise mechanism. A high-fat diet-induced hyperlipidemia model using C57BL/6J mice and HaCaT cells was established. Co-immunoprecipitation and immunofluorescence were performed to detect protein interactions, and immunoprecipitation coupled with Western blotting was used to assess protein succinylation. 40 μM of curcumin administration promoted cell viability, increased the levels of glutathione peroxidase, glutathione, catalase, and superoxide dismutase, while reducing reactive oxygen species activity and the levels of triglycerides and malondialdehyde. Additionally, curcumin attenuated the development of hyperlipidemia in vivo. Mechanistically, 100 mg/kg of curcumin promoted O-GlcNAcylation and increased the expression of O-linked N-acetylglucosamine transferase in HaCaT cells. Furthermore, apolipoprotein C3 was identified as a substrate of O-linked N-acetylglucosamine transferase, and O-GlcNAcylation of apolipoprotein C3 enhanced its stability. Rescue experiments further verified that curcumin exerts its effects by regulating apolipoprotein C3 expression. In conclusion, these findings provide novel insights into the treatment of hyperlipidemia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Hulunbuir Zhong Meng Hospital, Hulunbuir 021000, China; Department of Cardiology, Shouguang Hospital of T.C.M, Weifang 262700, China.
- Department of Cardiology, Qingdao Municipal Hospital, University of Health and Rehabilitation Sciences, Qingdao 266011, China.
- Department of Cardiology, Hulunbuir Zhong Meng Hospital, Hulunbuir 021000, China.
- Department of Science and Education, Hulunbuir Zhong Meng Hospital, Hulunbuir 021000, China.
- Department of Cardiology, Hulunbuir Zhong Meng Hospital, Hulunbuir 021000, China. Electronic address: yuliu716@163.com.
Förderung
- Hubei Association for Science and Technology
Zitieren
APA
Sun, G., Xu, Y., Liang, X., Wang, L., & Liu, Y. (2025). Curcumin inhibits the progression of hyperlipidemia via OGT mediated O-GlcNAcylation modulation of APOC3. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.113647
Vancouver
Sun G, Xu Y, Liang X, Wang L, Liu Y. Curcumin inhibits the progression of hyperlipidemia via OGT mediated O-GlcNAcylation modulation of APOC3. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2024.113647
BibTeX
@article{Sun2025,
author = {Sun, Guotong and Xu, Yaowen and Liang, Xiuwen and Wang, Lei and Liu, Yu},
title = {Curcumin inhibits the progression of hyperlipidemia via OGT mediated O-GlcNAcylation modulation of APOC3},
journal = {International Immunopharmacology},
year = {2025},
doi = {10.1016/j.intimp.2024.113647}
}
EUVIMED